Literature DB >> 23998275

Understanding HPV tests and their appropriate applications.

H A Cubie1, K Cuschieri.   

Abstract

Greater understanding of the role played by human papillomavirus (HPV) in the causation of disease has led to the development of an increasing number of HPV tests with different characteristics. The bewildering choice facing healthcare professionals and providers is daunting. Clearly, HPV testing is no longer simply of research interest, but can provide information that can be used for individual patient management and at the population level for cervical screening and vaccine surveillance. This review aims to provide the background to the development of HPV tests, to explain the different technologies and to discuss the challenges of the application of these optimally in the varied contexts of disease management. Few HPV tests are approved for clinical use and it is important that clinicians understand which test can be utilized, in what circumstances, with what specimens and the meaning of the report issued. HPV testing is no longer applicable only to cervical disease, and we have suggested additional areas, such as the oropharynx, in which HPV testing services might be implemented in the near future. New tests will continue to emerge and we have identified some of the indirect measures of HPV activity, or biomarkers, that could help in the risk stratification of HPV infection and associated disease. The challenges relating to the optimal application of the various HPV technologies are compounded by the lack of evidence regarding their performance in vaccinated populations. Currently published work, including modelling studies, has been undertaken in non-immunized populations. We therefore end by addressing the issues regarding appropriate strategies and tests for immunized populations.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  cervical screening; clinically approved/validated; human papillomavirus tests; human papillomavirus vaccine; molecular technologies; oropharyngeal cancer management

Mesh:

Year:  2013        PMID: 23998275     DOI: 10.1111/cyt.12083

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  13 in total

1.  High risk HPV testing following treatment for cervical intraepithelial neoplasia.

Authors:  M Molloy; R Comer; P Rogers; M Dowling; P Meskell; K Asbury; M O'Leary
Journal:  Ir J Med Sci       Date:  2015-12-21       Impact factor: 1.568

Review 2.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

3.  HPV status and therapeutic initial strategy impact on survival and oncologic outcomes: 5-year results from the multicentric prospective cohort of oropharyngeal cancers Papillophar.

Authors:  Dorian Culié; Alexandra Rousseau; Jean-Luc Pretet; Jean Lacau Saint Guily
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-18       Impact factor: 2.503

4.  Comparison of Three Different Commercial Kits for the Human Papilloma Virus Genotyping.

Authors:  Yong Kwan Lim; Jee-Hye Choi; Serah Park; Oh Joo Kweon; Ae Ja Park
Journal:  J Clin Lab Anal       Date:  2016-04-28       Impact factor: 2.352

Review 5.  Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer.

Authors:  Sonia N Whang; Maria Filippova; Penelope Duerksen-Hughes
Journal:  Viruses       Date:  2015-09-17       Impact factor: 5.048

6.  A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.

Authors:  Vânia Sammartino Mariano; Adriana Tarlá Lorenzi; Cristovam Scapulatempo-Neto; Maíra Degiovani Stein; Julio Cesar Possati Resende; Márcio Antoniazzi; Luisa Lina Villa; José Eduardo Levi; Adhemar Longatto-Filho; José Humberto Tavares Guerreiro Fregnani
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

7.  Universal Human Papillomavirus Typing Assay: Whole-Genome Sequencing following Target Enrichment.

Authors:  Tengguo Li; Elizabeth R Unger; Dhwani Batra; Mili Sheth; Martin Steinau; Jean Jasinski; Jennifer Jones; Mangalathu S Rajeevan
Journal:  J Clin Microbiol       Date:  2016-12-14       Impact factor: 5.948

8.  Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.

Authors:  K Cuschieri; D T Geraets; C Moore; W Quint; E Duvall; M Arbyn
Journal:  J Clin Microbiol       Date:  2015-08-05       Impact factor: 5.948

9.  Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.

Authors:  Darrel A Cook; Wendy Mei; Laurie W Smith; Dirk J van Niekerk; Kathy Ceballos; Eduardo L Franco; Andrew J Coldman; Gina S Ogilvie; Mel Krajden
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

10.  Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population.

Authors:  Pamela Moussavou-Boundzanga; Ismaël Hervé Koumakpayi; Ingrid Labouba; Eric M Leroy; Ernest Belembaogo; Nicolas Berthet
Journal:  Virol J       Date:  2017-12-21       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.